Aa
A
A
Close
Avatar universal
Isis antisense targeting reduces all markers in HBV
Many companies have come to the table, first one with the cure gets to turn out the light. I think that one of these treatments will find success in the next 4 years and end HBV for those who suffer from it.


- Chronic HBV infection is one of the most common persistent viral infections in the world. Currently available therapies, although effective in reducing circulating HBV in the blood, do not efficiently inhibit HBV antigen production and secretion, which are associated with poor prognosis and increased risk of liver cancer," said Dr. Stefan Wieland, assistant professor of experimental virology at The Scripps Research Institute.  "These data are encouraging as they demonstrate that antisense drugs are able to efficiently reduce HBV-associated antigens as well as circulating HBV in an animal model of disease.  As such, these results provide support for the development of ISIS-HBVRx for the treatment of patients with chronic HBV infection."


http://finance.yahoo.com/news/isis-announces-antisense-targeting-hbv-110000879.html
Cancel
1 Answers
1 Answers
Page 1 of 1
Avatar universal
Poster paper at EASL

link : https://pbs.twimg.com/media/BjfrzOXCEAEThox.png
Comment
Cancel
Avatar universal
Comment
Comment
Submit Comment
Your Answer
Avatar universal
Answer
Know how to answer? Tap here to leave your answer...
Answer
Submit Answer
A
A
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis B Community Resources
RSS Expert Activity
233488 tn?1310696703
Blank
Marathon Running Done Over Many Yea...
May 21 by John C Hagan III, MD, FACS, FAAOBlank
233488 tn?1310696703
Blank
New Article on Multifocal IOL vs &q...
May 21 by John C Hagan III, MD, FACS, FAAOBlank
748543 tn?1443740527
Blank
TMJ/TMJ The Connection Between Teet...
01/15 by Hamidreza Nassery , DMD, FICOI, FAGD, FICCMOBlank
Top Hepatitis Answerers